解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察  

Clinical Observation of Jiedu Fuzheng Decoction Combined with EGFR TKIs on Elderly Patients with Advanced Lung Cancer

作　　者：姚菲[1] 王家晓[1] 李春姗[1] 石玮[1] 

机构地区：[1]广西中医药大学第一附属医院,广西南宁530023

出　　处：《大众科技》2020年第12期57-60,共4页Popular Science & Technology

基　　金：广西自然科学基金项目(2019JJB140156);广西中医药大学自然科学研究课题项目(2018MS017);广西卫生和计划生育委员会自筹经费课题(Z20170284);广西中医药适宜技术开发与推广项目(GZSY20-22)。

摘　　要：目的:分析经验方解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者临床疗效的影响及其对免疫功能和炎症因子水平的影响。方法:在广西中医药大学第一附属医院信息系统中检索2017年4月至2020年4月收治的IV期年龄大于70岁的肺癌患者,患者均为EGFR基因突变类型,均接受EGFR TKIs药物治疗,对照组单纯口服TKIs治疗,观察组在口服TKIs基础上联合解毒复正汤,前后共服药8周,观察两组患者服药前后生活质量,外周血免疫指标及炎性因子的表达水平,评估解毒复正汤是否与调节患者外周血免疫功能及炎症指标相关。结果:最终筛选出89例患者,其中对照组44例,观察组45例,8周服药前后对比两组患者,观察组患者的SGRQ生活质量、外周血炎症因子表达及免疫功能等方面均较对照组改善(P<0.05)。结论:解毒复正汤联合EGFR-TKIs治疗可能通过提高患者的免疫功能,抑制外周炎性因子表达水平相关。结论:解毒复正汤及TKIs口服联合治疗模式较单纯TKIs口服治疗能更好改善老年肺癌患者生活质量,其机制可能与提高患者的免疫功能,抑制外周炎性因子表达水平相关。Objective:To analyze the effect of Jiedu Fuzheng decoction combined with EGFR TKIs on the clinical efficacy of elderly patients with advanced lung cancer and its influence on immune function and inflammatory factors.Methods:From April 2017 to April 2020,we searched the information system of the First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine for patients with stage IV lung cancer older than 70 years old.All patients were EGFR gene mutation type and received EGFR TKIs drug treatment.The control group was treated with oral TKIs treatment,while the observation group was treated with Jiedu Fuzheng Decoction on the basis of oral administration of TKIs,the drug was administered for 8 weeks before and after.The quality of life,the expression of immune indexes and inflammatory factors in peripheral blood of the two groups were observed before and after treatment,and whether Jiedu Fuzheng decoction was related to the regulation of peripheral blood immune function and inflammatory indexes was evaluated.Results:89 patients were finally screened out,including 44 cases in the control group and 45 cases in the observation group.The quality of life of SGRQ,the expression of inflammatory factors in peripheral blood and immune function of patients in the observation group were better than those in the control group before and after 8 weeks of medication(P<0.05).Conclusion:Jiedu Fuzheng decoction combined with EGFR TKIs may improve the immune function and inhibit the expression of peripheral inflammatory factors.Jiedu Fuzheng decoction combined with TKIs oral therapy can improve the quality of life of elderly patients with lung cancer,and its mechanism may be related to improving the immune function and inhibiting the expression of peripheral inflammatory factors.

关 键 词：解毒复正汤 EGFR-TKIS 晚期肺癌 老年肺癌 回顾性分析 

分 类 号：R734[医药卫生—肿瘤]